146 related articles for article (PubMed ID: 18395443)
1. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
Ruel R; Thibeault C; L'Heureux A; Martel A; Cai ZW; Wei D; Qian L; Barrish JC; Mathur A; D'Arienzo C; Hunt JT; Kamath A; Marathe P; Zhang Y; Derbin G; Wautlet B; Mortillo S; Jeyaseelan R; Henley B; Tejwani R; Bhide RS; Trainor GL; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 May; 18(9):2985-9. PubMed ID: 18395443
[TBL] [Abstract][Full Text] [Related]
2. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
Bhide RS; Cai ZW; Zhang YZ; Qian L; Wei D; Barbosa S; Lombardo LJ; Borzilleri RM; Zheng X; Wu LI; Barrish JC; Kim SH; Leavitt K; Mathur A; Leith L; Chao S; Wautlet B; Mortillo S; Jeyaseelan R; Kukral D; Hunt JT; Kamath A; Fura A; Vyas V; Marathe P; D'Arienzo C; Derbin G; Fargnoli J
J Med Chem; 2006 Apr; 49(7):2143-6. PubMed ID: 16570908
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
5. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
[TBL] [Abstract][Full Text] [Related]
7. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
8. Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE; Norris D; Mastalerz H; Chen P; Goyal B; Zhao Y; Kim SH; Vite GD; Lee FY; Zhang H; Oppenheimer S; Tokarski JS; Wong TW; Gavai AV
Bioorg Med Chem Lett; 2011 Jan; 21(2):781-5. PubMed ID: 21177105
[TBL] [Abstract][Full Text] [Related]
9. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
Wong TW; Lee FY; Emanuel S; Fairchild C; Fargnoli J; Fink B; Gavai A; Hammell A; Henley B; Hilt C; Hunt JT; Krishnan B; Kukral D; Lewin A; Malone H; Norris D; Oppenheimer S; Vite G; Yu C
Clin Cancer Res; 2011 Jun; 17(12):4031-41. PubMed ID: 21531814
[TBL] [Abstract][Full Text] [Related]
10. Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.
Xiang HY; Wang X; Chen YH; Zhang X; Tan C; Wang Y; Su Y; Gao ZW; Chen XY; Xiong B; Gao ZB; Chen Y; Ding J; Meng LH; Yang CH
Eur J Med Chem; 2021 Jan; 209():112913. PubMed ID: 33109399
[TBL] [Abstract][Full Text] [Related]
11. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.
Gavai AV; Fink BE; Fairfax DJ; Martin GS; Rossiter LM; Holst CL; Kim SH; Leavitt KJ; Mastalerz H; Han WC; Norris D; Goyal B; Swaminathan S; Patel B; Mathur A; Vyas DM; Tokarski JS; Yu C; Oppenheimer S; Zhang H; Marathe P; Fargnoli J; Lee FY; Wong TW; Vite GD
J Med Chem; 2009 Nov; 52(21):6527-30. PubMed ID: 19821562
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).
Regueiro-Ren A; Xue QM; Swidorski JJ; Gong YF; Mathew M; Parker DD; Yang Z; Eggers B; D'Arienzo C; Sun Y; Malinowski J; Gao Q; Wu D; Langley DR; Colonno RJ; Chien C; Grasela DM; Zheng M; Lin PF; Meanwell NA; Kadow JF
J Med Chem; 2013 Feb; 56(4):1656-69. PubMed ID: 23360431
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.
Hunt JT; Mitt T; Borzilleri R; Gullo-Brown J; Fargnoli J; Fink B; Han WC; Mortillo S; Vite G; Wautlet B; Wong T; Yu C; Zheng X; Bhide R
J Med Chem; 2004 Jul; 47(16):4054-9. PubMed ID: 15267243
[TBL] [Abstract][Full Text] [Related]
14. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
16. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
[TBL] [Abstract][Full Text] [Related]
18. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
[TBL] [Abstract][Full Text] [Related]
19. (
Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
